Recent developments with Abbott Laboratories (ABT) have led to the company’s beta value being reach 0.74 cents.

A new trading day began on Monday, with Abbott Laboratories (NYSE: ABT) stock price down -0.20% from the previous day of trading, before settling in for the closing price of $109.11. ABT’s price has ranged from $89.67 to $121.64 over the past 52 weeks.

Annual sales at Healthcare sector company grew by 6.10% over the past five years. Meanwhile, its annual earnings per share averaged 4.02%. With a float of $1.72 billion, this company’s outstanding shares have now reached $1.73 billion.

Let’s look at the performance matrix of the company that is accounted for 114000 employees.

Abbott Laboratories (ABT) Insider and Institutional Ownership

As we move forward, let’s examine how large-scale investors are investing in this stock of the Medical Devices Industry. The insider ownership of Abbott Laboratories is 0.74%, while institutional ownership is 77.10%. The most recent insider transaction that took place on Mar 01 ’24, was worth 114,116. In this transaction EXECUTIVE VICE PRESIDENT of this company sold 963 shares at a rate of $118.50, taking the stock ownership to the 125,697 shares. Before that another transaction happened on Mar 01 ’24, when Company’s EXECUTIVE VICE PRESIDENT sold 853 for $118.50, making the entire transaction worth $101,080. This insider now owns 184,806 shares in total.

Abbott Laboratories (ABT) Latest Financial update

Wall Street market experts anticipate that the next fiscal year will bring earnings of 108.89 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 4.02% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.80% during the next five years compared to 19.65% growth over the previous five years of trading.

Abbott Laboratories (NYSE: ABT) Trading Performance Indicators

Here are Abbott Laboratories’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.16. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.71. Likewise, its price to free cash flow for the trailing twelve months is 37.35.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 3.27, a number that is poised to hit 0.95 in the next quarter and is forecasted to reach 5.14 in one year’s time.

Technical Analysis of Abbott Laboratories (ABT)

Abbott Laboratories (NYSE: ABT) saw its 5-day average volume 4.23 million, a negative change from its year-to-date volume of 5.57 million. As of the previous 9 days, the stock’s Stochastic %D was 23.76%. Additionally, its Average True Range was 1.98.

During the past 100 days, Abbott Laboratories’s (ABT) raw stochastic average was set at 43.81%, which indicates a significant increase from 7.21% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 18.27% in the past 14 days, which was higher than the 16.54% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $114.61, while its 200-day Moving Average is $106.71. Nevertheless, the first resistance level for the watch stands at $110.24 in the near term. At $111.60, the stock is likely to face the second major resistance level. The third major resistance level sits at $112.30. If the price goes on to break the first support level at $108.18, it is likely to go to the next support level at $107.48. The third support level lies at $106.13 if the price breaches the second support level.

Abbott Laboratories (NYSE: ABT) Key Stats

With a market capitalization of 188.94 billion, the company has a total of 1,735,184K Shares Outstanding. Currently, annual sales are 40,109 M while annual income is 5,723 M. The company’s previous quarter sales were 10,241 M while its latest quarter income was 1,594 M.